Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study

Kim Linton(The Christie NHS Foundation Trust), Julie M. Vose(University of Nebraska Medical Center), Michael Roost Clausen(Vejle Sygehus), Martine E.D. Chamuleau(Hovon), Diana Gernhardt(Genmab (United States)), Catherine Thiéblemont(Université Paris Cité), Brian Hess(Washington University in St. Louis), Elena Favaro(Genmab (Denmark)), Daniela Hoehn(Columbia University Irving Medical Center), Tara Cochrane(Gold Coast Hospital), Sirpa Leppä(University of Helsinki), Martin Hutchings(University of Copenhagen), Pieternella J. Lugtenburg(Erasmus MC Cancer Institute), Brian Elliott(Genmab (United States)), Tahamtan Ahmadi(Genmab (United States)), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Raúl Córdoba(Hospital Universitario Fundación Jiménez Díaz), Emmanuel Gyan(Inserm), Juan‐Manuel Sancho(Hospital Universitari Germans Trias i Pujol), Craig Okada(Oregon Health & Science University), Yan Liu(Genmab (United States)), Wojciech Jurczak(Jagiellonian University), David Lewis(University Hospitals Plymouth NHS Trust), Jacob Haaber Christensen(Odense University Hospital), Işıl Altıntaş(Genmab (Netherlands)), Umberto Vitolo(Candiolo Cancer Institute), Minh H. Dinh(AbbVie (United States)), Hervé Tilly(Centre Virchow-Villermé)
The Lancet Haematology
June 15, 2024
Cited by 134


Related Papers